Zobrazeno 1 - 10
of 33
pro vyhledávání: ''
Autor:
Gary E. Pickard, Rajamouli Pasula, Rhonda D. Cardin, David A. Dixon, Gregory A. Smith, David I. Bernstein, Patricia J. Sollars, Fernando J. Bravo
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-8 (2020)
NPJ Vaccines
NPJ Vaccines
Herpes simplex virus (HSV) infections are common and can cause severe illness but no vaccine is currently available. The recent failure of subunit HSV vaccines has highlighted the need for vaccines that present a diverse array of antigens, including
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-9 (2020)
NPJ Vaccines
NPJ Vaccines
In 2018, the Bill and Melinda Gates Foundation convened over thirty subject matter experts in clinical development, manufacturing, and regulatory assessment to determine how the development and approval of medical countermeasures could be accelerated
Autor:
Poolman, Jan T.
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-12 (2020)
NPJ Vaccines
NPJ Vaccines
A crisis in bacterial infections looms as ageing populations, increasing rates of bacteraemia and healthcare-associated infections converge with increasing antimicrobial resistance and a paucity of new antimicrobial classes. New initiatives are neede
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-13 (2020)
npj Vaccines
NPJ Vaccines
npj Vaccines
NPJ Vaccines
Vaccines represent the most successful medical intervention in history, with billions of lives saved. Although multiple doses of the same vaccine are typically required to reach an adequate level of protection, it would be advantageous to develop vac
Autor:
Johannes P. M. Langedijk, Renske Bolder, Eirikur Saeland, Jan Serroyen, Roland Zahn, Hanneke Schuitemaker, Marjolein Heemskerk-van der Meer, Yolinda van Polanen, Joke Drijver, Leslie van der Fits
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-9 (2020)
NPJ Vaccines
NPJ Vaccines
While RSV is a major cause of respiratory morbidity in infants, vaccine development is hindered by the immaturity and Th2-bias of the infant immune system and the legacy of enhanced respiratory disease (ERD) after RSV infection following immunization
Autor:
Gemma Moncunill, Itziar Ubillos, Ross L. Coppel, Augusto Nhabomba, Inocencia Cuamba, Sheetij Dutta, Pedro Aide, Nana Aba Williams, Chenjerai Jairoce, Evelina Angov, Deepak Gaur, Lina Sánchez, David R. Cavanagh, Marta Vidal, Carlota Dobaño, Ruth Aguilar, James G. Beeson, Joseph J. Campo, Núria Díez-Padrisa
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-16 (2020)
Dipòsit Digital de la UB
Universidad de Barcelona
NPJ Vaccines
Sanchez, L, Vidal, M, Jairoce, C, Aguilar, R, Ubillos, I, Cuamba, I, Nhabomba, A J, Williams, N A, Díez-padrisa, N, Cavanagh, D, Angov, E, Coppel, R L, Gaur, D, Beeson, J G, Dutta, S, Aide, P, Campo, J J, Moncunill, G & Dobaño, C 2020, ' Antibody responses to the RTS,S/AS01E vaccine and plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique ', Human vaccines, vol. 5, no. 1 . https://doi.org/10.1038/s41541-020-0192-7
Dipòsit Digital de la UB
Universidad de Barcelona
NPJ Vaccines
Sanchez, L, Vidal, M, Jairoce, C, Aguilar, R, Ubillos, I, Cuamba, I, Nhabomba, A J, Williams, N A, Díez-padrisa, N, Cavanagh, D, Angov, E, Coppel, R L, Gaur, D, Beeson, J G, Dutta, S, Aide, P, Campo, J J, Moncunill, G & Dobaño, C 2020, ' Antibody responses to the RTS,S/AS01E vaccine and plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique ', Human vaccines, vol. 5, no. 1 . https://doi.org/10.1038/s41541-020-0192-7
The RTS,S/AS01 - " vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 clinical trial using a 3-dose immunization schedule. A fourth-dose 18 months after the primary vaccination was shown to restore the waning efficacy. H
Autor:
Celia C. LaBranche, Benjamin Mildenberg, Sampa Santra, Andrea Cara, Barton F. Haynes, Erich J Baker, Donatella R.M. Negri, Maria Blasi, Mary E. Klotman, M. Anthony Moody, Wes Rountree, Kevin O. Saunders, Elizabeth C Wescott
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-9 (2020)
npj Vaccines
NPJ Vaccines
npj Vaccines
NPJ Vaccines
Despite incredible scientific efforts, there is no cure for HIV infection. While antiretroviral treatment (ART) can help control the virus and prevent transmission, it cannot eradicate HIV from viral reservoirs established before the initiation of th
Autor:
Paul J.M. Roholl, Nicolas Collin, Harry van Dijken, Martin Friede, Paulo Lee Ho, José A Ferreira, Femke de Heij, Rineke de Jong, Eduardo Alfredo Adami, Sanne Spijkers, Milena Apetito Akamatsu, Justin Mouthaan, Willem Luytjes, Livia Brunner, Jørgen de Jonge
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-14 (2020)
npj Vaccines 5 (2020) 1
NPJ Vaccines
npj Vaccines, 5(1)
npj Vaccines 5 (2020) 1
NPJ Vaccines
npj Vaccines, 5(1)
Until universal influenza vaccines become available, pandemic preparedness should include developing classical vaccines against potential pandemic influenza subtypes. We here show that addition of SWE adjuvant, a squalene-in-water emulsion, to H7N9 s
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-5 (2020)
Vaccine-enhanced disease (VED) occurs as a result of vaccination followed by infection with virulent Mycoplasma pneumoniae. To date VED has prevented development of an efficacious vaccine against this significant human respiratory pathogen. Herein we
Autor:
Q. David Walker, Cynthia M. Kuhn, Bruce E. Blough, Soman N. Abraham, Herman F. Staats, Hae Woong Choi, Ashley L. St. John
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-9 (2020)
NPJ Vaccines
NPJ Vaccines
Cocaine is one of the most potent and addictive psychostimulants known and there are no available pharmacotherapies to treat cocaine addiction. Here we describe a novel cocaine vaccine employing the mucosal adjuvant and mast cell-activating oligopept